Prospective study of the evaluation of hepatitis C virus infectivity in a high-purity, solvent/detergent-treated factor VIII concentrate: parallel evaluation of other markers for lipid-enveloped and non-lipid-enveloped viruses. The Ad Hoc Study Group of the Fondazione dell'Emofilia
- PMID: 8236421
- DOI: 10.1046/j.1537-2995.1993.331094054617.x
Prospective study of the evaluation of hepatitis C virus infectivity in a high-purity, solvent/detergent-treated factor VIII concentrate: parallel evaluation of other markers for lipid-enveloped and non-lipid-enveloped viruses. The Ad Hoc Study Group of the Fondazione dell'Emofilia
Abstract
This prospective study was carried out with the aim of evaluating the efficacy of solvent/detergent inactivation of the hepatitis C virus (HCV) as applied to a chromatographic factor VIII concentrate. In parallel, the markers for other viruses, either lipid-enveloped (human immunodeficiency virus types 1 and 2 [HIV-1 and -2] and hepatitis B virus [HBV]) or non-lipid-enveloped viruses (such as B19 parvovirus and hepatitis A virus [HAV]) were evaluated. The study included 14 hemophilia centers, which enrolled 36 previously untreated patients (median age, 3 years; range, 1-56). The length of follow-up was 12 months, during which HCV (first- and second-generation assays and recombinant immunoblot assay), HIV-1 and -2, HBV, HAV (IgG and IgM), and parvovirus (IgG and IgM) antibodies, as well as alanine aminotransferase values were evaluated. Thirty-one patients were analyzable; none seroconverted for HCV, HBV, or HIV after exposure to a total of 165,000 IU of factor VIII (41 different lots). In one patient, alanine aminotransferase values rose to 167 mU per mL, 6 weeks after the first concentrate infusion, and this patient seroconverted for HAV 1 week later. Furthermore, 10 patients seroconverted for parvovirus during follow-up. This study suggests that the solvent/detergent method of virus inactivation is efficient in relation to lipid-enveloped blood-borne viruses but not in relation to non-lipid-enveloped viruses.
Similar articles
-
Transmission of parvovirus B19 by coagulation factor concentrates exposed to 100 degrees C heat after lyophilization.Transfusion. 1997 May;37(5):517-22. doi: 10.1046/j.1537-2995.1997.37597293884.x. Transfusion. 1997. PMID: 9149778
-
Low risk for hepatitis C in hemophiliacs given a high-purity, pasteurized factor VIII concentrate. International Study Group.Ann Intern Med. 1990 Jul 1;113(1):27-32. doi: 10.7326/0003-4819-113-1-27. Ann Intern Med. 1990. PMID: 2112352 Clinical Trial.
-
[Evaluation of viral safety of a high-purity human factor VIII concentrate submitted to 2 specific virus inactivation treatments (FANDHI)].Sangre (Barc). 1996 Apr;41(2):131-6. Sangre (Barc). 1996. PMID: 9045353 Spanish.
-
Viral safety of solvent-detergent treated blood products.Dev Biol Stand. 1993;81:147-61. Dev Biol Stand. 1993. PMID: 8174797 Review.
-
Clinical evaluation of viral safety of coagulation factor VIII and IX concentrates.Vox Sang. 1993;64(4):197-203. doi: 10.1111/j.1423-0410.1993.tb03055.x. Vox Sang. 1993. PMID: 8517048 Review.
Cited by
-
Preclinical safety and efficacy of a new recombinant FIX drug product for treatment of hemophilia B.Int J Hematol. 2013 Nov;98(5):525-32. doi: 10.1007/s12185-013-1448-z. Epub 2013 Sep 24. Int J Hematol. 2013. PMID: 24061775 Free PMC article.
-
Hepatitis C: progress and problems.Clin Microbiol Rev. 1994 Oct;7(4):505-32. doi: 10.1128/CMR.7.4.505. Clin Microbiol Rev. 1994. PMID: 7834603 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials